
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
Brand Name | Status | Last Update |
|---|---|---|
| eplerenone | ANDA | 2025-08-19 |
| inspra | New Drug Application | 2025-06-23 |
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| systolic heart failure | EFO_1001207 | D054143 | I50.20 |
| hypertension | EFO_0000537 | D006973 | I10 |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 2 | — | — | — | — | 2 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 1 | — | — | — | — | 1 |
| Drug common name | Eplerenone |
| INN | eplerenone |
| Description | Eplerenone, sold under the brand name Inspra, is an aldosterone antagonist type of potassium-sparing diuretic that is used to treat chronic heart failure and high blood pressure, particularly for patients with resistant hypertension due to elevated aldosterone. It is a steroidal antimineralocorticoid of the spirolactone group and a selective aldosterone receptor antagonist (SARA). Eplerenone is more selective than spironolactone at the mineralocorticoid receptor relative to binding at androgen, progestogen, glucocorticoid, or estrogen receptors.
|
| Classification | Small molecule |
| Drug class | aldosterone antagonists (spironolactone type) |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@H]13 |
| PDB | — |
| CAS-ID | 107724-20-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1095097 |
| ChEBI ID | 31547 |
| PubChem CID | 5282131 |
| DrugBank | DB00700 |
| UNII ID | 6995V82D0B (ChemIDplus, GSRS) |








